A cost-effectiveness analysis of genetic testing of the DRD2 Taq1A polymorphism to aid treatment choice for smoking cessation.

A cost-effectiveness analysis of genetic testing of the DRD2 Taq1A polymorphism to aid treatment choice for smoking cessation. Nicotine Tob Res. 2008 Jan; 10(1):231-40.

View in: PubMed

subject areas

Alleles
Bupropion
Combined Modality Therapy
Cost of Illness
Cost-Benefit Analysis
Counseling
Dopamine Uptake Inhibitors
Genetic Testing
Humans
Models, Economic
Nicotine
Polymorphism, Genetic
Receptors, Dopamine D2
Smoking
Smoking Cessation

authors with profiles

Sean P. David